MedImmune in-licenses cancer immunotherapy tremelimumab from Pfizer

Monday, 3 October 2011

MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody. Under the terms of this agreement, MedImmune will assume global development rights to tremelimumab and Pfizer will retain the rights to use tremelimumab with specified types of combination therapies. MedImmune plans to explore tremelimumab in a number of potential cancer indications. Terms of the agreement were not disclosed.

Read the full press release

Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar